Multiple omics analyses and experiments validation identify PRDX3 as a biomarker of prognosis and antioncogene in kidney clear cell carcinoma
Fig 10
PRDX3 inhibited KIRC progression via regulating PPAR signaling pathway.
A: KEGG pathway enrichment of PRDX3. B: Scatter plot of correlation of PRDX3 with PPARA. C and D: Western blot and qPCR showing high PPARA expression in PRDX3 over-expressing cells. The qPCR was shown using (n = 3) mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. E and F: PRDX3 promoting Bax, BMF, and Bim expressions and inhibiting CCND, CCL20 and MMP9 expressions. Data (n = 3) are shown as mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. G, H and I: wound healing, migration and invasion abilities suppressed after adding PPAR inhibitor. Data (n = 3) are shown as mean ± standard error (SE), * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001.